January 11, 2021 The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive™ ALIVER is a consortium focused on developing a new treatment for patients with liver failure for whom there are no specific approved therapies, apart from liver transplantation. The Consortium is composed of partners from across Europe, led by University College London (UCL), and includes Yaqrit Ltd, a life sciences company and intellectual property owner of Dialive™, the European Association for the Study of the Liver ( and the EF Clif, amongst others.

The Consortium is developing and testing a novel blood filtration system, DIALIVE, whose design is based on 20 years of research led by Professor Rajiv Jalan, Professor Nathan Davies and members of the Liver Failure Group at UCL. Yaqrit Ltd was spun off from UCL in 2014 to develop and potentially commercialise treatments including Dialive™ for patients with advanced liver disease. Professor Jalan is the lead scientific founder of Yaqrit.

The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive™ device compared to the control group. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733057.

Download attached document (662,71 KB)